Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.

Meyer, Sara C. (2017). Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. Hematology/oncology clinics of North America, 31(4), pp. 627-642. Elsevier 10.1016/j.hoc.2017.04.003

Text 1-s2.0-S0889858817300606-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (662kB) | Request a copy

Myeloproliferative neoplasms are driven by activated JAK2 signaling due to somatic mutations in JAK2, the thrombopoietin receptor MPL or the chaperone calreticulin in hematopoietic stem/progenitor cells. JAK2 inhibitors have been developed, but despite clinical benefits, they do not signficantly reduce the mutant clone. Loss of response to JAK2 inhibitors occurs and several mechanisms of resistance, genetic and functional, have been identified. Resistance mutations have not been reported in MPN patients suggesting incomplete target inhibition. Alternative targeting of JAK2 by HSP90 inhibitors or type II JAK2 inhibition overcomes resistance to current JAK2 inhibitors. Additional combined therapy approaches are currently being evaluated.

Interest & Impact

Downloads

1 since deposited on 22 Dec 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item